Since going public, Veraxa Biotech has endured a deep slump that has pushed its stock into single-digit territory. Its recovery may hinge on the adoption of new drug-testing protocols to accelerate its clinical pipeline.

Veraxa's chief scientific officer, Christopher Erkel, framed the shift as "not just a regulatory obligation, but a scientific opportunity." The move aligns with the Food and Drug Administration's push to phase out animal testing and target a major shift by the end of the decade.

Instead of using animals, drugmakers have been urged to harness alternative methods like lab-grown human cells, computer simulations, and real human tissue samples, all of which provide a more accurate picture of how drugs will work in patients.

The FDA's framework establishes clear timelines for phasing out animal testing wherever suitable alternatives exist, unlike prior industry guidance. Veraxa already has started integrating human-relevant models into its research, with Erkel noting Wednesday that the company had been exploring alternatives long before the FDA rolled out its roadmap last year.

"We see this shift as beneficial and a win-win situation for both science and sustainability," Erkel added. He expects lower reliance on animal models, particularly toxicology testing in nonhuman primates, to spur the generation of richer human data, and in turn making drug development faster and cheaper.

For the general public, animal testing is often an unseen aspect of drug development, and one that frequently fails to deliver actual benefits to patients. According to the FDA, over 90% of drugs that show promise in animal models fail to achieve regulatory clearance, largely due to unforeseen safety issues or a lack of efficacy.

Beyond overcoming ethical issues associated with animal testing, getting drugs to market faster would be good for Veraxa, which has yet to commercialize a single product since its founding in 2021. The German biotech is the product of a merger of spin-outs from the European Molecular Biology Laboratory.

The company went public through a blank-check merger with Voyager Acquisition Corp. in June. Its initiation into the public markets has been brutal: Through Tuesday's close of trading, shares have fallen nearly 96% since its June 11 trading debut. Veraxa's market value currently hovers around $159.6 million, making it a textbook example of a micro-cap player.

The company faces an uphill battle in an increasingly crowded market. Veraxa's focus on next-generation cancer therapies, namely antibody-drug conjugates and T-cell engagers, reflects a broader industry pivot toward highly targeted, next-generation immunotherapies -- a space aggressively pursued by major players like AstraZeneca and AbbVie.